Long-term safety of gastroretentive gabapentin in postherpetic neuralgia patients

Clinical Journal of Pain

Volumn 29, Issue 9, 2013, Pages 770-774

  Jensen, Mark P ^a   Irving, Gordon ^b   Rauck, Richard ^c   Wallace, Mark ^d   Sweeney, Mike ^e   Vanhove, Geertrui F ^e,f  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Swedish Pain and Headache Center   (United States)

^c Center for Clinical Research   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Pharmacokinetics Depomed Inc   (United States)

^f JAZZ PHARMACEUTICALS   (United States)

Author keywords

gabapentin; gastroretentive; postherpetic neuralgia

Indexed keywords

GABAPENTIN;

ARTHRALGIA; ARTICLE; CAROTID ARTERY OBSTRUCTION; CONTROLLED STUDY; DEPRESSION; DERMATITIS; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HEART INFARCTION; HOT FLUSH; HUMAN; HYPERTRANSAMINASEMIA; INSOMNIA; JOINT SWELLING; LONG TERM CARE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCULOSKELETAL PAIN; NEUROLOGIC EXAMINATION; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PNEUMONIA; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SOMNOLENCE; THROMBOCYTE COUNT; UPPER RESPIRATORY TRACT INFECTION; VIRAL GASTROENTERITIS; WEIGHT CHANGE; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

EID: 84881541338     PISSN: 07498047     EISSN: 15365409     Source Type: Journal    
DOI: 10.1097/AJP.0b013e31827b32ab     Document Type: Article

References (28)

1. Johnson RW, Wasner G, Saddier P, et al. Postherpetic neuralgia: epidemiology, pathophysiology and management. Expert Rev Neurother. 2007; 7:1581-1595. (Pubitemid 350106836)
2. Sampathkumar P, Drage LA, Martin DP. Herpes zoster (shingles) and postherpetic neuralgia. Mayo Clin Proc. 2009; 84:274-280.
3. Bowsher D. The management of postherpetic neuralgia. Postgrad Med. 1997; 73:623-629. (Pubitemid 27464457)
4. Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010; 17:1113-1123.
5. Dubinsky RM, Kabbani H, El-Chami Z, et al. Practice parameter: treatment of postherpetic neuralgia. Neurology. 2004; 63:959-965.
6. Rowbotham M, Harden N, Stacey B, et al. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA. 1998; 280:1837-1842. (Pubitemid 28544424)
7. Rice AS, Maton S. Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. Pain. 2001; 94:215-224. (Pubitemid 33016615)
8. Backonja M, Glanzman RL. Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. Clin Ther. 2003; 25:81-104. (Pubitemid 36206739)
9. Gidal BE, Maly MM, Nemire RE, et al. Weight gain and gabapentin therapy. Ann Pharmacother. 1995; 29:1048.
10. DoToledo JC, Toledo C, Decerce J, et al. Changes in body weight with chronic, high-dose gabapentin therapy. Ther Drug Monit. 1997; 19:394-396. (Pubitemid 28074034)
11. Siler AC, Gardner H, Yanit K, et al. Systematic review of the comparative effectiveness of antiepileptic drugs for fibromyalgia. J Pain. 2011; 12:407-415.
12. Bogan RK, Bornemann MA, Kushida CA, et al. Long-term maintenance treatment of restless legs syndrome with gabapentin enacarbil: a randomized controlled study. Mayo Clin Proc. 2010; 85:512-521.
13. Ellenbogen AL, Thein SG, Winslow DH, et al. A 52-week study of gabapentin enacarbil in restless legs syndrome. Clin Neuropharmacol. 2011; 34:8-16.
14. Schwartz S, Fonseca V, Berner B, et al. Efficacy, tolerability, and safety of a novel once-daily extended-release metformin in patients with type 2 diabetes. Diabetes Care. 2006; 29: 759-764. (Pubitemid 44115290)
15. Gralises (gabapentin) prescribing information. Depomed Inc., Menlo Park, CA; April 2011. Available at http://www.gralise.com. Accessed February 27, 2012.
16. Stewart BH, Kugler AR, Thompson PR, et al. A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. Pharmacol Res. 1993; 10:276-281. (Pubitemid 23041744)
17. Gordi T, Hou E, Kasichayanula S, et al. Pharmacokinetics of gabapentin after a single day and at steady state following the administration of gastric-retentive-extended-release and immediate release tablets: a randomized, open-label, multiple-dose, three-way crossover, exploratory study in healthy subjects. Clin Ther. 2008; 30:909-916. (Pubitemid 351799872)
18. Chen C, Cowles VE, Hou E. Pharmacokinetics of gabapentin in a novel gastric-retentive extended-release formulation: comparison with an immediate release formulation and effect of dose escalation with food. J Clin Pharmacol. 2011; 51: 346-358.
19. Irving G, Jensen M, Cramer M, et al. Efficacy and tolerability of gastric-retentive gabapentin for the treatment of postherpetic neuralgia: results of a double-blind, randomized, placebocontrolled trial. Clin J Pain. 2009; 25:185-192.
20. Wallace MS, Irving G, Cowles VE. Gabapentin extendedrelease tablets for the treatment of patients with postherpetic neuralgia: a randomized, double-blind, placebo-controlled, multicenter study. Clin Drug Investig. 2010; 30:765-776.
21. Sang C, Sathyanarayana R, Carter F, et al. Gabapentin extended release for the once-daily treatment of post herpetic neuralgia. American Academy of Pain Management 21st Annual Meeting; Las Vegas, NV, September 2010.
22. Ojemann LM, Wilensky AJ, Temkin NR, et al. Long-term treatment with gabapentin for partial epilepsy. Epilepsy Res. 1992; 13:159-165.
23. Lhatoo SD, Wong ICK, Polizzi G, et al. Long-term retention rates of lamotrigine, gabapentin, and topiramate in chronic epilepsy. Epilepsia. 2000; 41:1592-1596. (Pubitemid 32002733)
24. Putzke JD, Richards JS, Kezar L, et al. Long-term use of gabapentin for treatment of pain after traumatic spinal cord injury. Clin J Pain. 2002; 18:116-121. (Pubitemid 34205402)
25. US Gabapentin study group. The long-term safety and efficacy of gabapentin (Neurontin) as add-on therapy in drug resistant partial epilepsy. Epilepsy Res. 1994; 18:67-73.
26. Ben-Menachem E. Weight issues for people with epilepsy - a review. Epilepsia. 2007; 48(suppl 9):42-45. (Pubitemid 350198229)
27. McLean MJ, Morrell MJ, Willmore J, et al. Safety and tolerability of gabapentin as adjunctive therapy in a large, multicenter study. Epilepsia. 1999; 40:965-972. (Pubitemid 29316052)
28. Sabatowski R, Galvez R, Cherry DA, et al. Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomized, placebocontrolled clinical trial. Pain. 2004; 109:26-35. (Pubitemid 38479767)